72 related articles for article (PubMed ID: 8996850)
1. Parametrization by nonlinear regression analysis of the active acid metabolite of ebastine using different weighting methods.
Mariño EL; Jansat JM; March MA; Lastra CF
Int J Clin Pharmacol Ther; 1996 Dec; 34(12):546-9. PubMed ID: 8996850
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastine after intravenous administration in healthy volunteers.
Jansat JM; Lastra CF; Mariño EL
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):340-4. PubMed ID: 9660043
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
[TBL] [Abstract][Full Text] [Related]
4. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects.
Huang MY; Argenti D; Wilson J; Garcia J; Heald D
Am J Ther; 1998 May; 5(3):153-8. PubMed ID: 10099053
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys.
Matsuda M; Sakashita M; Mizuki Y; Yamaguchi T; Fujii T; Sekine Y
Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872
[TBL] [Abstract][Full Text] [Related]
8. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants.
Shon JH; Yeo CW; Liu KH; Lee SS; Cha IJ; Shin JG
J Clin Pharmacol; 2010 Feb; 50(2):195-204. PubMed ID: 19841159
[TBL] [Abstract][Full Text] [Related]
9. Studies on the first-pass metabolism of ebastine in rats.
Fujii T; Matsumoto S; Hatoyama T; Miyazaki H
Arzneimittelforschung; 1997 Aug; 47(8):949-53. PubMed ID: 9296281
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
Noveck RJ; Preston RA; Swan SK
Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.
Chaikin P; Gillen MS; Malik M; Pentikis H; Rhodes GR; Roberts DJ
Br J Clin Pharmacol; 2005 Mar; 59(3):346-54. PubMed ID: 15752381
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs.
Puigdemont A; Queralt M; Jansat JM; Martinez-Tobed A
J Pharm Pharmacol; 1994 Jul; 46(7):596-9. PubMed ID: 7996390
[TBL] [Abstract][Full Text] [Related]
13. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
[TBL] [Abstract][Full Text] [Related]
14. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine.
Van Rooij J; Schoemaker HC; Bruno R; Reinhoudt JF; Breimer DD; Cohen AF
Br J Clin Pharmacol; 1993 Jun; 35(6):661-3. PubMed ID: 8101096
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry.
Kang W; Liu KH; Ryu JY; Shin JG
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):75-80. PubMed ID: 15556518
[TBL] [Abstract][Full Text] [Related]
16. The effect of food on the bioavailability of ebastine.
Pentikis HS; Huang MY; Dorr MB; Heald DL
Am J Ther; 1997; 4(2-3):80-4. PubMed ID: 10423596
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.
Vincent J; Liminana R; Meredith PA; Reid JL
Br J Clin Pharmacol; 1988 Nov; 26(5):497-502. PubMed ID: 2905150
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of ebastine in children.
Simons FE; Watson WT; Simons KJ
J Pediatr; 1993 Apr; 122(4):641-6. PubMed ID: 8096545
[TBL] [Abstract][Full Text] [Related]
19. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
Rodríguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
[TBL] [Abstract][Full Text] [Related]
20. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
